东北制药集团股份有限公司 一、本人已经通过东北制药集团股份有限公司第十届董事会提 名委员会资格审查，提名人与本人不存在利害关系或者其他可能影 响独立履职情形的密切关系 是 □ 否 如否，请详细说明：______________________________ 二、本人不存在《中华人民共和国公司法》第一百七十八条等 规定不得担任公司董事的情形。 是 □ 否 如否，请详细说明：______________________________ 三、本人符合中国证监会《上市公司独立董事管理办法》和深 圳证券交易所业务规则规定的独立董事任职资格和条件。 独立董事候选人声明与承诺 声明人曹越，作为东北制药集团股份有限公司第十届董事会独 立董事候选人，已充分了解并同意由提名人东北制药集团股份有限 公司董事会提名为东北制药集团股份有限公司（以下简称该公司） 第十届董事会独立董事候选人。现公开声明和保证，本人与该公司 之间不存在任何影响本人独立性的关系，且符合相关法律、行政法 规、部门规章、规范性文件和深圳证券交易所业务规则对独立董事 候选人任职资格及独立性的要求，具体声明并承诺如下事项： 是 □ 否 1 如否，请详细说明：___ ...

证券代码：000597 证券简称：东北制药 公告编号：2025-046 东北制药集团股份有限公司 关于召开公司 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、召开会议的基本情况 1.股东大会届次：本次股东大会为公司 2025 年第一次临时股东大会。 2.股东大会的召集人：公司董事会。2025 年 6 月 4 日，东北制药集团股份有 限公司（以下简称"公司"）第十届董事会第三次会议，以同意 9 票，反对 0 票， 弃权 0 票审议通过了《关于召开公司 2025 年第一次临时股东大会的议案》。 3.会议召开的合法、合规性：公司第十届董事会第三次会议决定召开本次股 东大会。本次股东大会会议召开符合有关法律、行政法规、部门规章、规范性文 件、深圳证券交易所业务规则和《东北制药集团股份有限公司章程》等的规定。 4.会议召开的日期、时间： （1）现场会议召开时间：2025 年 6 月 20 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 6 月 20 日 9:15—9:25，9: ...

证券代码：000597 证券简称：东北制药 公告编号：2025-045 东北制药集团股份有限公司 第十届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 本议案在董事会审议前，已通过公司董事会审计委员会、提名委员会审核。 该议案尚需提交公司股东大会审议。 议案二：关于变更公司第十届董事会董事的议案 1.东北制药集团股份有限公司（以下简称"公司"）第十届董事会第三次会 议于 2025 年 5 月 30 日发出会议通知，于 2025 年 6 月 4 日以通讯表决的方式召 开。 2.会议应参加董事 9 人，实际参加董事 9 人。 3.本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和《东北制药集团股份有限公司章程》的规定，会议形成的决议合法 有效。 二、董事会会议审议情况 会议审议并以记名投票表决方式通过以下议案： 议案一：关于补选公司第十届董事会独立董事的议案 同意选举曹越先生为公司第十届董事会独立董事，任期自公司股东大会审议 通过之日起至第十届董事会届满之日止。 具体内容详见公司于同日披 ...

Group 1 - The core point of the article is the significant stock price increases of several pharmaceutical companies following the approval of 11 innovative drugs by the National Medical Products Administration on May 29 [1] Group 2 - Harbin Pharmaceutical Group (哈三联) reached the daily limit increase in stock price [1] - Companies such as Ruizhi Pharmaceutical (睿智医药), Xinnowei (新诺威), Hainan Haiyao (海南海药), and Huasen Pharmaceutical (华森制药) saw stock price increases of over 5% [1] - Other companies including Fosun Pharma (复星医药), Yipinhong (一品红), Haiwang Biological (海王生物), and Northeast Pharmaceutical (东北制药) also experienced stock price increases [1]

Group 1 - The core viewpoint is that Northeast Pharmaceutical is transforming from a traditional manufacturing enterprise to a technology-driven pharmaceutical group through its "Digital Dongyao" strategy and forward-looking layout in the biopharmaceutical field [1] - The company is enhancing production efficiency and product quality through intelligent manufacturing, utilizing new technologies such as big data, cloud computing, and artificial intelligence [2] - Northeast Pharmaceutical is actively promoting green production and energy management to contribute to sustainable development [2] Group 2 - The company is focusing on biopharmaceutical innovation as a key direction for transformation, increasing R&D investment, and accelerating new drug development [3] - Northeast Pharmaceutical has established a collaborative R&D framework across Shenyang, Beijing, and Shanghai, optimizing its product structure based on clinical needs [3] - The company has launched 22 new products since 2021 and is entering the cell therapy market through the acquisition of Dingcheng Peptide Source in 2024 [3]

Group 1 - BYD reported August sales of 174,915 new energy vehicles, a year-on-year increase of 184.84% [1] - Cumulative sales from January to August reached 978,795 units, representing a year-on-year growth of 267.31% [1] - The company sold 5,092 new energy passenger vehicles overseas in August [1] Group 2 - Zhongke Electric's subsidiary plans to establish a joint venture with Chongqing Fudi for the production of anode materials, with a registered capital of 1 billion RMB [2] - Zhongke Electric's subsidiary will contribute 650 million RMB, while Chongqing Fudi will contribute 350 million RMB [2] Group 3 - Yuyuan Group intends to transfer 13% of its shares in Jinhuijiu for approximately 1.937 billion RMB, reducing its stake to 25% [3] - The company plans to further reduce its holdings by more than 5% within the next six months [3] Group 4 - Lizhu Group's recombinant COVID-19 fusion protein vaccine has been included in the emergency use for sequential booster immunization [4] Group 5 - Guanghui Energy plans to repurchase shares worth between 800 million and 1 billion RMB to support employee stock ownership plans [5] Group 6 - Cambrian has launched four cloud-based intelligent chips, although mass sales will require a longer time frame and initial technical service investments [7] Group 7 - LePu Medical has received approval from the China Securities Regulatory Commission for the issuance of Global Depositary Receipts (GDRs) and listing on the Swiss Stock Exchange [9] - The GDR issuance will correspond to no more than 180,458,875 new A-shares [9] Group 8 - Fushi Holdings' subsidiary has entered into an exclusive advertising agency cooperation with the Central Radio and Television Station's automotive channel for three years [10] Group 9 - Guangzhou Port's container throughput in August was 1.981 million TEUs, a year-on-year increase of 2.4% [11] - The total cargo throughput for August was 44.788 million tons, a decrease of 0.6% [11] Group 10 - Ningbo Port expects to complete a container throughput of 3.58 million TEUs in August, a year-on-year increase of 10.2% [12] - The total cargo throughput is projected to decline by 3.0% [12] Group 11 - Ming Tai Aluminum reported a 7% year-on-year decrease in aluminum plate and strip sales in August, while aluminum profile sales increased by 47% [13] Group 12 - Electric Power Investment plans to invest in multiple wind and solar projects, with total static investments of 1.585 billion RMB for wind and 538 million RMB for solar [14] Group 13 - Northeast Pharmaceutical has signed a cooperation agreement with MedAbome for the development of the MAb11-22.1 antibody project [19] Group 14 - New Five Feng plans to acquire equity in Tianxin Seed Industry and several other companies for a total price of approximately 2.208 billion RMB [26] Group 15 - Sumeida's subsidiary plans to transfer 100% equity of eight photovoltaic power station project companies, with an estimated transaction value of 657 million RMB [27] Group 16 - *ST Tongzhou intends to acquire 51% equity in Tongtaiwei, fulfilling the capital contribution obligation of 10.2 million RMB [29] Group 17 - Tianyin Holdings' subsidiary plans to invest 120 million RMB in Xundong Xintong to acquire 40% equity [30] Group 18 - Hainan Haiyao plans to publicly transfer 43% equity in Shanghai Lishengte to attract new investors [31] Group 19 - New Asia Process plans to transfer 7.76% of its shares to Xiangcai New Materials at a price of 5.274 RMB per share [32] Group 20 - Lanwei Medical plans to raise no more than 664 million RMB through a private placement for provincial laboratory construction projects [34] Group 21 - Lida New Materials plans to issue convertible bonds to raise no more than 300 million RMB for a new aluminum material project [35] Group 22 - Gekewei has successfully launched its 12-inch CIS integrated circuit project, achieving over 95% yield [51] Group 23 - Baijin Medical's tricuspid valve ring product has received registration approval [52] Group 24 - Shanghai Pharmaceuticals has received approval to initiate Phase I clinical trials for a recombinant anti-CD20 humanized monoclonal antibody [53] Group 25 - Junda Co. has increased the production capacity of its solar cell production base project from 8GW to 10GW [54]

Core Viewpoint - Northeast Pharmaceutical is committed to strategic transformation through innovation and management reform, aiming to enhance operational quality and transition from a traditional chemical drug leader to a biopharmaceutical leader [1] Group 1: Strategic Focus and Innovation - The company is focusing on strategic acquisitions, particularly the acquisition of Dingcheng Peptide Source, to commercialize innovative results in cell therapy [1][2] - Northeast Pharmaceutical has established a product matrix covering various fields, including oncology and autoimmune diseases, driven by a dual strategy of "innovative drugs + generic drugs" [2][3] - The company has developed over 10 tumor-targeted cell immunotherapy products, with DCTY1102 injection expected to be the first domestic TCR-T cell drug entering Phase I clinical trials targeting KRAS G12D [2] Group 2: Management and Efficiency - Since implementing mixed ownership reform in 2018, the company has adopted new management and incentive models, enhancing operational quality and efficiency [4] - The company has achieved a 20.5% year-on-year reduction in sales expenses and an 88% increase in R&D expenses, reflecting precise resource allocation [4] - Financial stability is indicated by a decreasing debt-to-asset ratio and a significant reduction in current liabilities, lowering short-term repayment risks [4] Group 3: Global Expansion - Northeast Pharmaceutical has a strong international presence, exporting products to over 100 countries, with a notable increase in overseas sales revenue of 9.02 billion yuan, up 26.3% year-on-year [6][7] - The company is optimizing its marketing system to enhance market share and brand influence, particularly in the competitive vitamin C and phosphomycin markets [6][7] - The global layout provides a broader platform and resources, allowing the company to diversify market risks and enhance its competitive edge in international markets [7]

Core Insights - Liaoning Fangda Group Northeast Pharmaceutical's Q1 2025 report shows a significant increase in R&D investment by 88% year-on-year, indicating a strategic shift towards R&D-driven growth and quality enhancement over mere revenue increase [2][4] Group 1: Quality Improvement and Financial Health - Despite a slight revenue increase of 0.36% in Q1 2025, the company achieved steady improvement in operational quality through refined management and structural optimization [2] - Sales expenses decreased by 20.5% year-on-year, while management expenses also reduced, and R&D expenses rose strategically to 32 million yuan, reflecting precise resource allocation [2] - The company's debt-to-asset ratio fell to 58.82%, a decrease of 2.63 percentage points from the beginning of the year, indicating enhanced financial health and reduced short-term repayment risks [2] Group 2: Innovation and Product Development - Northeast Pharmaceutical is implementing a dual-driven strategy of "innovative drugs + generic drugs," creating a product matrix covering various therapeutic areas including neurology, digestion, endocrinology, oncology, and autoimmune diseases [3] - The company is accelerating its strategic layout in cutting-edge fields, particularly in tumor immunotherapy, with over 10 immune therapy products targeting diseases like pancreatic cancer and colorectal cancer [4] - A notable product in development is a TCR-T cell drug targeting KRASG12D, which is expected to be the first of its kind in China to enter Phase I clinical trials [4] Group 3: Global Market Expansion - The company is leveraging its international presence to enhance its global sales network, with its main products exported to over 100 countries and regions [5] - The global sales strategy has effectively diversified market risks and established sustainable revenue capabilities [5] - Although there may be short-term profit fluctuations due to increased R&D investments, the strategic transformation is showing initial positive results, positioning the company for future growth cycles as innovative therapies are commercialized [5]

Core Viewpoint - Northeast Pharmaceutical has demonstrated a notable performance in quality transformation through structural adjustments in the first quarter of 2025, despite a slight revenue increase of only 0.36% [1] Group 1: Financial Performance - The company achieved a 20.5% year-on-year reduction in sales expenses and a simultaneous decrease in management expenses, while strategically increasing R&D expenses to 32 million yuan, an 88% year-on-year surge [2] - As of the end of the first quarter, the company's debt-to-asset ratio decreased to 58.82%, down 2.63 percentage points from the beginning of the year, indicating improved financial health and reduced short-term repayment risks [2] Group 2: Innovation and R&D - Northeast Pharmaceutical is implementing a dual-driven strategy of "innovative drugs + generic drugs," covering multiple therapeutic areas including the nervous system, digestive system, and oncology, which highlights its long-term growth potential [3] - The company has accelerated its strategic layout in cutting-edge fields of innovative drugs, with a significant increase in R&D funding aimed at tumor immunotherapy, a key trend in the global pharmaceutical industry [3] - The company has developed over 10 targeted cell immunotherapy products for various cancers, with DCTY1102 injection expected to be the first TCR-T cell drug targeting KRAS G12D to enter Phase I clinical trials in China [3] Group 3: Competitive Strategy - The company has consolidated its competitive advantage through a "combination of innovation and imitation" strategy, with 243 product specifications included in the national medical insurance catalog and 120 in the national essential drug list, providing a stable foundation for performance growth [4] - This dual-driven model of "innovative drugs leading and generic drugs supporting" ensures short-term performance certainty while opening up long-term growth opportunities [4] Group 4: Global Strategy - The company is leveraging its international gene advantage to enhance its global sales network, with its leading products exported to over 100 countries and regions, thereby diversifying market risks and creating sustainable revenue streams [5] - Despite short-term profit fluctuations, the company's strategic transformation is showing initial results, with management reforms and future-oriented R&D investments leading to significant improvements in operational quality [5] - As the innovative drug pipeline matures and the global strategy deepens, Northeast Pharmaceutical is transitioning from a traditional pharmaceutical company to a leader in biotechnology, with the commercialization of cell therapies expected to initiate a new growth cycle [5]

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The hyaluronic acid food market is experiencing significant growth driven by increasing health awareness and regulatory support, with the market size projected to grow from 6.8 billion to 18.8 billion from 2019 to 2023, and expected to reach 34.6 billion by 2028 [7][8] - The industry is characterized by a fragmented market structure with a few leading brands, and the demand for hyaluronic acid products is rapidly increasing due to consumer interest in health and beauty [15][16] Market Background - Hyaluronic acid is a natural component found in the human body, and its application in food products is a new segment within health foods. The domestic brands are well-positioned in the market due to technological breakthroughs and capacity releases in upstream production [4][5] - The market for food-grade hyaluronic acid is expanding, with significant regulatory milestones achieved, allowing its use in ordinary food products [6] Market Status - The market size for hyaluronic acid food products in China has grown significantly, with a compound annual growth rate (CAGR) of 42.05% from 2019 to 2023 in the number of approved products, indicating a strong upward trend in consumer demand [8][10] - The supply side is bolstered by advancements in production technology, particularly microbial fermentation, which has improved production efficiency and reduced costs [9] Market Competition - The competitive landscape is divided into three tiers, with leading companies like Tongrentang and Xianle Health in the second tier, and brands like Yanruyu in the third tier [15][16] - The report highlights ten recommended brands, including Huaxi Biological, which is a global leader in the hyaluronic acid sector, and Tongrentang, known for integrating traditional medicine with modern health products [16][17][20] Development Trends - The industry is witnessing a trend of upstream and downstream integration, with leading producers focusing on technological innovations to enhance product quality and reduce costs [27] - Consumer demand is becoming increasingly segmented, with products tailored for different demographics, such as beauty drinks for younger consumers and joint health supplements for the elderly [28] - Cross-industry collaborations and brand partnerships are emerging as a significant trend, allowing brands to leverage each other's market presence and expand their product offerings [29][30]